| Chemotherapy Rechallenge or Reintroduction compared to Regorafenib or Trifluridine/Tipiracil for pretreated metastatic colorectal cancer patients: a PROpensity ScorE analysis … MA Calegari, IV Zurlo, E Dell'Aquila, M Basso, A Orlandi, M Bensi, ... Clinical Colorectal Cancer, 2024 | | 2024 |
| Simultaneous Integrated Boost (Sib) Intensity-Modulated Radiotherapy for Treatment of Bone Metastases: Analysis of a Breast Cancer Cohort F Marazzi, V Masiello, A Fabi, S Manfrida, B Corvari, V Lancellotta, ... Preprints, 2024 | | 2024 |
| CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer M Pérol, BJ Solomon, K Goto, K Park, E Nadal, E Bria, C Martin, J Bar, ... Journal of Clinical Oncology, JCO. 24.00724, 2024 | | 2024 |
| To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding ‘Abemaciclib plus a nonsteroidal aromatase … A Orlandi, L Mastrantoni, E Bria, G Tortora Annals of Oncology, 2024 | | 2024 |
| Bevacizumab in combination with chemotherapy for treating patients with advanced RET+ non-small cell lung cancer. M Aldea, A Marinello, I Monnet, H de Saint Basile, S Cousin, ... Journal of Clinical Oncology 42 (16_suppl), 8647-8647, 2024 | | 2024 |
| Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study. M Perol, K Goto, BJ Solomon, K Park, E Nadal, E Bria, C Martin, J Bar, ... Journal of Clinical Oncology 42 (16_suppl), 8547-8547, 2024 | | 2024 |
| Correlation between multiorgan immune-related adverse events and clinical outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) treated with chemo … F Monaca, MI Gomez-Randulfe Rodriguez, E Vita, A Cosmai, S Polidori, ... Journal of Clinical Oncology 42 (16_suppl), e20129-e20129, 2024 | | 2024 |
| Gender minorities in breast cancer–Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients F Miglietta, L Pontolillo, C De Angelis, R Caputo, M Marino, E Bria, ... The Breast 75, 103713, 2024 | | 2024 |
| Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative Review F Lococo, G Ghaly, M Chiappetta, S Flamini, J Evangelista, E Bria, ... Cancers 16 (10), 1832, 2024 | | 2024 |
| Abstract PO2-01-14: Development of Artificial Intelligence-based Machine Learning Models for Predicting Survival In Hormone-Receptor-Positive/HER2-Negative Early Breast Cancer … L Mastrantoni, G Garufi, N Maliziola, ED Monte, G Arcuri, V Frescura, ... Cancer Research 84 (9_Supplement), PO2-01-14-PO2-01-14, 2024 | | 2024 |
| Abstract PO4-15-06: Genomic landscape characterization after exposure to cyclin dependent kinase 4/6 inhibitors: a retrospective multi-institutional consortium analysis L Pontolillo, C Reduzzi, A Davis, L Gerratana, A Medford, K Clifton, ... Cancer Research 84 (9_Supplement), PO4-15-06-PO4-15-06, 2024 | | 2024 |
| Abstract PO3-14-11: Association between BRCA alterations detected by circulating tumor DNA and germline mutations in breast cancer patients: a retrospective mono-institutional … L Pontolillo, E Nicolò, LM Arcos, C Reduzzi, MS Serafini, AK Strickland, ... Cancer Research 84 (9_Supplement), PO3-14-11-PO3-14-11, 2024 | | 2024 |
| 254P Development of machine learning models for the prediction of early progression (EP) to first-line (1L) cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) therapy in … S Pannunzio, L Mastrantoni, L Pontolillo, G Garufi, E Di Monte, ... ESMO Open 9, 2024 | | 2024 |
| Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed A Leonetti, F Perrone, M Puntoni, G Maglietta, P Bordi, E Bria, E Vita, ... European Journal of Cancer 202, 114006, 2024 | | 2024 |
| Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced nonsmall cell lung cancer E Vita, F Monaca, D Milardi, L Mastrantoni, A Stefani, E Vergani, J Russo, ... Cancer, 2024 | | 2024 |
| Germline BRCA1/2 mutations detected by circulating tumor DNA testing in breast cancer patients: A retrospective mutiinstitutional analysis L Pontolillo, C Reduzzi, AA Davis, AJ Medford, A Putur, L Gerratana, ... Cancer Research 84 (6_Supplement), 977-977, 2024 | | 2024 |
| Accessible Machine Learning and Deep Learning Models Predict Response and Survival in Early Stage Hormone Receptor-Positive/HER2-Negative Breast Cancer Receiving Neoadjuvant … G Garufi, L Mastrantoni, G Giordano, N Maliziola, E Di Monte, G Arcuri, ... | | 2024 |
| 201P Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: An international multicentric analysis MIGR Rodriguez, C Escriu, S Mohammed, R Shah, JDB Fuentes, S Cox, ... ESMO Open 9, 2024 | | 2024 |
| 52P Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03 … A Leonetti, R Minari, M Pluchino, F Passiglia, AS Bianchi, DL Cortinovis, ... ESMO Open 9, 2024 | | 2024 |
| 234P Clinical findings and genomic characterization of NRG-1 alterations with a comprehensive genome profiling (CGP) in advanced non-small cell lung cancer (ANSCLC) E Vita, L Mastrantoni, A Scala, A Vitale, A Stefani, F Monaca, J Russo, ... ESMO Open 9, 2024 | | 2024 |
Diana GiannarelliFondazione Policlinico Universitario A. Gemelli IRCCS Rome在 policlinicogemelli.it 的电子邮件经过验证
